Isorhamnetin from Astragalus membranaceus exerts anti-glioma effects via PI3K/Akt signaling pathway.
AI Summary
Key Findings
Abstract
This study examined the antitumor effects and molecular mechanisms of isorhamnetin in glioma treatment with a particular focus on its regulation of the PI3K/Akt signaling pathway, for developing targeted therapies. Using network pharmacology, we identified isorhamnetin could be used as a potential active ingredient in the regulation of glioblastoma (GBM) through the PI3K/Akt pathway. Bibliometric analysis was then used to review the current state and the developing trends in isorhamnetin research for anti-tumor applications. It was confirmed that isorhamnetin exerts its effects via the PI3K/Akt pathway. Our in vitro experiments showed further that isorhamnetin inhibits the proliferation and migration of glioma cells in a dose-dependent manner. Furthermore, isorhamnetin downregulated proteins related to the PI3K/Akt pathway, thereby suppressing its signaling activity. Isorhamnetin has antitumor effects against glioma by modulating the PI3K-Akt signaling pathway, providing experimental and mechanistic evidence for the potential use of isorhamnetin as a complementary GBM therapy.
Affiliation
Mingming Luo
External References
- PubMed ID:
- 41657804
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.